Abstracts tagged "Sjögren’s syndrome"

Abstract Number: 1538 • ACR Convergence 2022
Decreased Prevalence of Autoimmune Connective Tissue Diseases in Type 1 and Type 2 Diabetes
Aya abugharbyeh, Sadik Khuder and bashar Kahaleh, University of Toledo, Toledo, OH
Background/Purpose: Evidence suggest that autoimmune diseases tend to coexist at a higher rate than expected, reflecting a common pathogenetic pathway. However, data sets have shown…
Abstract Number: 2024 • ACR Convergence 2022
Salivary Gland Ultrasound May Lead to a More Accurate Stratification of Patients with the Same Serological Profile in Sjögren’s Syndrome: Towards a Personalized Approach
Silvia Fonzetti¹, Francesco Ferro², Gaetano La Rocca³, Giovanni Fulvio⁴, Inmaculada Concepción Navarro García⁵, Gianmaria Governato⁶, Valentina Donati⁷, Marta Mosca⁸ and Chiara Baldini⁴, ¹Azienda Ospedaliera Universitaria Pisana, Pisa, Italy, ²Clinical and Experimental Medicine Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Pisa, Italy, ³University of Pisa, Rheumatology Unit, Palermo, Palermo, Italy, ⁴University of Pisa, Pisa, Pisa, Italy, ⁵Clinical and Experimental Medicine Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy, ⁶Azienda Ospedaliera Universitaria Pisana, Pisa, Pisa, Italy, ⁷Pathology Unit, University of Pisa, Pisa, Italy, ⁸Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
Background/Purpose: Salivary gland ultrasound (SGUS) abnormalities have been increasingly recognized as possible biomarkers for Sjögren's Syndrome (SS) phenotypic stratification. However, to date few studies have…
Abstract Number: 2040 • ACR Convergence 2022
Metformin Improves Objective Measures of Dry Eyes and Focus Score in Sjögren′s Disease: A Retrospective Observational Study
Astrid Rasmussen¹, R. Hal Scofield², Kiely Grundahl¹, Lida Radfar², Christopher Lessard¹ and A. Darise Farris¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Metformin (dimethyl biguanide, Met) is a widely used, first-line antidiabetic drug with AMPK-dependent anti-inflammatory and immunomodulatory effects. In vitro studies and human trials in…
Abstract Number: 0302 • ACR Convergence 2021
Loss of TAM Receptor Mer Contributes to Sjögren’s Syndrome–like Disease in Mice
Richard Witas and Cuong Nguyen, University of Florida, Gainesville, FL
Background/Purpose: Sjögren’s syndrome (SjS) is a chronic autoimmune disease primarily involving the exocrine glands where the involvement of the innate immune system is largely uncharacterized.…
Abstract Number: 0318 • ACR Convergence 2021
Correlation Between Prognostic Nutritional Index and Primary Sjögren’s Syndrome Disease Activity
Kbra Kalkan¹, Ufuk Ilgen², Zeliha Ademoğlu³ and Hakan Emmungil³, ¹trakya uviversity, istanbul, Turkey, ²Trakya University Medical School, Department of Rheumatology, Edirne, Turkey, ³Trakya University, Edirne, Turkey
Background/Purpose: Since primary Sjögren’s Syndrome (pSS) is a very heterogeneous disease with systemic manifestations, factors influencing the outcome of patients with pSS need to be…
Abstract Number: 1841 • ACR Convergence 2021
Presence of Autoantibodies to Dense-Fine-Speckled 70 (DFS70) Do Not Necessarily Rule out Connective Tissue Diseases
Louisa-Marie Mockenhaupt¹, Ramona Dolscheid-Pommerich¹, Charlotte Behning¹, Birgit Stoffel-Wagner², Peter Brossart¹ and Valentin Schäfer¹, ¹University Hospital Bonn, Bonn, Germany, ²University Hospital Bonn, Bonn
Background/Purpose: Antinuclear antibodies (ANA) are serological markers for the presence of connective tissue diseases [1]. In some patients, a pattern can be detected in ANA…
Abstract Number: 0303 • ACR Convergence 2021
Extraglandular Manifestations as Initial Presentation in a Cohort of Patients with Primary Sjögren’s Syndrome
Lucia Alascio¹, Silvia Papasidero¹, María Alejandra Medina¹, Juan Manuel Bande¹, Silvana Perez¹, Eliana Serrano¹, Diana Klajn¹, Jose Caracciolo¹, Rosella Tralice², Erick Rodríguez², Felix Romanini², Anastasia Secco², Sinda Zalles³, Carolina Segura Escobar³, Julia Demarchi³, Geofredo Guillermo Earsman⁴, Laura Raiti⁵, Sofia Velez⁶ and Alejandro Martinez⁷, ¹Hospital General de Agudos Dr. Enrique Tornú, Buenos Aires, Argentina, ²Hospital Rivadavia, Buenos Aires, Buenos Aires, Argentina, ³Hospital Británico, Buenos Aires, Buenos Aires, Argentina, ⁴Hospital Británico, Buenos Aires, La Lucila, Argentina, ⁵Clínica Bessone, Buenos Aires, Buenos Aires, Argentina, ⁶Consultorio privado de reumatología, Buenos Aires, Argentina, ⁷Fundación respirar, Buenos Aires, Mexico City, Mexico
Background/Purpose: Primary Sjögren's Syndrome (pSS) is a systemic autoimmune disease which is mostly characterized by the presence of xerophthalmia and xerostomia, caused by the lymphoplasmacytic…
Abstract Number: 0319 • ACR Convergence 2021
Assessment of EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI) Domains in Routine Clinical Practice in an Integrated Delivery Network in the United States
Briana Ndife¹, Irina Pivneva², Carmine Rossi² and James Signorovitch³, ¹Novartis, East Hanover, NJ, ²Analysis Group, Inc., Montréal, QC, Canada, ³Analysis Group, Inc., Boston, MA
Background/Purpose: Sjögren's syndrome (SS) is a chronic autoimmune disease associated with diverse phenotypes, which may include systemic disease activity. In real-world practice, the clinical presentation…
Abstract Number: 1908 • ACR Convergence 2021
Interferon (IFN)-Stimulated Gene 15: A Novel Biomarker for Lymphoma Development in Sjögren’s Syndrome
Ilir i. Cinoku¹, Kleio-Maria Verrou¹, Evangelia Piperi¹, Michael Voulgarelis², Haralampos Moutsopoulos³ and Clio Mavragani¹, ¹National and Kapodistrian University of Athens, Athens, Greece, ²Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, ³Athens Academy of Athens, Chair Medical Sciences/Immunology, Athens, Greece
Background/Purpose: Primary Sjögren’s syndrome (SS), an autoimmune exocrinopathy, is expressed either as a local disease or as a systemic illness with an enhanced risk for…
Abstract Number: 0304 • ACR Convergence 2021
Renal Involvement in Sjőgren’s Syndrome: Predictors and Impact on Patient Outcome
Rudrarpan Chatterjee¹, Anu Balakrishnan², Rajat Kharbanda¹, Upendra Rathore¹, Latika Gupta¹, Durga P Misra¹, Vikas Agarwal², Amita Aggarwal¹ and Able Lawrence², ¹Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India, ²Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
Background/Purpose: Renal disease in primary Sjogren's syndrome (pSS) can occur in form of tubulointerstitial nephritis (TIN) or glomerulonephritis (GN). Data from India on pSS is…
Abstract Number: 0320 • ACR Convergence 2021
Performance of the Clinical Trials ESSDAI (ClinTrialsESSDAI), an Adjusted ESSDAI Score, in Two Randomised Clinical Trials in Patients with Primary Sjögren’s Syndrome
Liseth de Wolff¹, Suzanne Arends², Elena Pontarini³, Michele Bombardieri³, Simon J Bowman⁴ and Hendrika Bootsma², ¹University Medical Centre Groningen, Groningen, Netherlands, ²University Medical Center Groningen, Groningen, Netherlands, ³Queen Mary University of London, William Harvey Research Institute, London, United Kingdom, ⁴Department of Rheumatology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom
Background/Purpose: Recent randomised controlled trials (RCTs) in primary Sjögren’s syndrome (pSS) failed to show clinical efficacy.1-3 Several RCTs used the EULAR Sjögren’s Syndrome Disease Activity…
Abstract Number: 1935 • ACR Convergence 2021
Skewed Escape from X-inactivation: Insights into the Female Bias of Sjögren’s Syndrome
Teressa Shaw¹, Wei Zhang², Sara McCoy³, Xueer Qiu¹, Adam Pagenkopf¹, Robert Hal Scofield⁴, Jacques Galipeau³ and Yun Liang¹, ¹University of Wisconsin-Madison, Madison, WI, ²University of California San Diego, La Jolla, CA, ³University of Wisconsin, Madison, WI, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Many autoimmune diseases feature increased prevalence in females, with primary Sjögren's syndrome (pSS) being the most female-predominant autoimmune disease with a female-to-male ratio of…
Abstract Number: 0305 • ACR Convergence 2021
Artificial Neural Networks Approaches to Predict Myocardial Fibrosis in Primary Sjögren Syndrome Patients Without Cardiac Symptoms
Hitomi Kobayashi¹, Yasuyuki Kobayashi², Atsuma Nishiwaki¹, Isamu Yokoe¹, Haraoka Masaki³, Eichi Takaya³, Yousuke Nagasawa¹, Noboru Kitamura¹, Masami Takei¹ and Hideki Nakamura¹, ¹Nihon University School of Medicine, Itabashi, Japan, ²St. Marianna University School of Medicine, kowasaki, Japan, ³St. Marianna University School of Medicine, Kawaski, Japan
Background/Purpose: A recent meta-analysis of cardiovascular diseases demonstrated that the odds of heart failure (HF) was more than 2.54-fold higher in primary Sjögren syndrome (pSS)…
Abstract Number: 0321 • ACR Convergence 2021
Sequential Administration of Belimumab and Rituximab in Primary Sjögren’s Syndrome Reduces Minor Salivary Gland–Resident B Cells and Delays B-Cell Repopulation in Circulation
André van Maurik¹, David Gardner², Saba Nayar², Charlotte Smith², Kenneth Clark¹, Prafull Mistry¹, Rajesh Punwaney³, David Roth³, Robert Henderson¹, Xavier Mariette⁴ and Francesca Barone², ¹GlaxoSmithKline, Stevenage, Hertfordshire, United Kingdom, ²University of Birmingham, College of Medical and Dental Sciences, Birmingham, United Kingdom, ³GlaxoSmithKline, Collegeville, PA, ⁴Université Paris- Saclay, Rheumatology, Paris, France
Background/Purpose: Primary Sjögren’s syndrome (pSS) is characterized by B-cell hyperactivity and elevated serum and saliva B-lymphocyte stimulator (BLyS) levels.1 Sequential administration of belimumab (BEL; anti-BLyS)…
Abstract Number: 0306 • ACR Convergence 2021
Allergic Disorders in Primary Sjögren’s Syndrome Compared with Rheumatoid Arthritis
Misako Higashida-Konishi¹, Keisuke Izumi², Tatsuya Shimada³, Satoshi Hama⁴, Mitsuhiro Akiyama⁵, Hisaji Oshima⁴ and Yutaka Okano⁶, ¹Department of Connective Tissue Diseases, National Hospital Organization Tokyo Medical Center, Meguroku, Japan, ²Department of Connective Tissue Diseases, National Hospital Organization Tokyo Medical Center/Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ³Department of Connective Tissue Diseases, National Hospital Organization Tokyo Medical Center/ Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, ⁴Department of Connective Tissue Diseases, National Hospital Organization Tokyo Medical Center, tokyo, Japan, ⁵Department of Connective Tissue Diseases, National Hospital Organization Tokyo Medical Center/ Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Palo Alto, CA, ⁶Department of Connective Tissue Diseases, National Hospital Organization Tokyo Medical Center, Kawasaki, Japan
Background/Purpose: Allergic disorders are occasionally seen in patients with primary Sjögren's syndrome (pSS) [1]. Risk factors are unclear for allergic disorders.We aimed to compare the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].